BOSTON, Sept. 29, 2026 (GLOBE NEWSWIRE) — Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that it has commenced a registered public offering (the “Offering”) of (i) shares of its common stock, or in lieu of common stock to certain investors, pre-funded warrants to purchase shares of common stock, and (ii) accompanying common warrants to purchase shares of common stock. Each share of common stock and each pre-funded warrant will be sold together with a common warrant to purchase one share of common stock.

The common warrants will become exercisable only upon approval by the Company’s stockholders of an amendment to the Company’s certificate of incorporation to increase the number of authorized shares of common stock and the effectiveness of that amendment (the date of such effectiveness, the “Charter Amendment Effective Date”), and will expire upon the earlier of (i) the fifth anniversary of the Charter Amendment Effective Date and (ii) the 30th calendar day following the later (x) of the Charter Amendment Effective Date and (y) the Company’s public disclosure of overall survival data (the “OS Data Release Date”) from its ongoing Phase 1 monotherapy study of micvotabart pelidotin (MICVO) in second-line and beyond (2L+) recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC), expected in the first half of 2027. All of the securities in the Offering are to be sold by Pyxis Oncology.

Leerink Partners, Guggenheim Securities and Wells Fargo Securities are acting as joint bookrunning managers for the proposed Offering. The proposed Offering is subject to market and other conditions, and there can be no assurance as to whether or when the Offering may be completed or as to the actual size or terms of the Offering.

Pyxis Oncology intends to use the net proceeds from the Offering to advance its lead clinical program, MICVO, through key clinical milestones, including Headliner™, its planned Phase 3 trial in 2L+ R/M HNSCC, and for working capital and general corporate purposes.

The common stock, common warrants and pre-funded warrants are being offered pursuant to a registration statement on Form S-3 (File No. 333-291801), which was previously filed with and subsequently declared effective by the Securities and Exchange Commission (the “SEC”). The Offering will be made only by means of a prospectus supplement and accompanying prospectus that form a part of the registration statement. A copy of the preliminary prospectus supplement relating to and describing the terms of the Offering will be filed with the SEC and will be available for free on the SEC’s website at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus may also be obtained, when available, from Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at 1-800-808-7525 ext. 6105, or by email at syndicate@leerink.com; Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com; or from Wells Fargo Securities, LLC, Attention: Equity Syndicate Department, 90 South 7th Street, 5th Floor, Minneapolis, Minnesota 55402, at (800) 645-3751 (option #5) or email a request to WFScustomerservice@wellsfargo.com.

This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in the Offering, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Pyxis Oncology

Pyxis Oncology, Inc. is a clinical-stage biopharmaceutical company developing therapeutics for difficult-to-treat cancers. The Company’s lead candidate, micvotabart pelidotin (MICVO), is a first-in-concept antibody-drug conjugate (ADC) that targets extradomain-B of fibronectin (EDB+FN), a non-cellular structural component of the tumor extracellular matrix (ECM). EDB+FN is selectively overexpressed in the tumor microenvironment of a wide range of solid tumors and largely absent from normal adult tissues. MICVO is designed to treat solid tumors through a three-pronged mechanism of action: direct cancer cell killing, bystander effect and immunogenic cell death. MICVO is currently being evaluated as monotherapy in a Phase 1 clinical study in patients with recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) and in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in a Phase 1/2 clinical study in patients with R/M HNSCC and other solid tumors. Pyxis Oncology is focused on advancing MICVO, with the goal of improving outcomes for patients living with R/M HNSCC and contributing to meaningful progress in cancer treatment.

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

Forward-Looking Statements

This press release contains forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained in this press release, including without limitation statements regarding the anticipated Offering, including its timing, size, terms and completion and the anticipated gross proceeds therefrom (including from any exercise of the common warrants); the Company’s ability to obtain stockholder approval of, and to effect, the amendment to its certificate of incorporation required for the common warrants to become exercisable, and the timing thereof; the timing of the OS Data Release Date, which will affect the period during which the common warrants may be exercised; the Company’s intended use of the net proceeds from the Offering; the Company’s plans to develop, manufacture and commercialize MICVO; the timing and progress of the Company’s ongoing clinical trials and the expected results thereof; the plans and objectives of management; and the future results of operations and financial position of the Company, are forward-looking statements. These statements are neither promises nor guarantees, but are statements that involve known and unknown risks, uncertainties and other important factors that are in some cases beyond the Company’s control that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: market and other conditions and the Company’s ability to complete the Offering on the anticipated terms, or at all; the Company’s ability to obtain the stockholder approval required for the common warrants to become exercisable; the timing and results of the overall survival analysis from the Company’s Phase 1 monotherapy study of MICVO; the risks inherent in drug research and development; the Company’s projected cash runway and potential needs for additional funding; the lengthy, expensive and uncertain process of clinical drug development, including potential delays in or failure to obtain regulatory approvals; the Company’s reliance on third parties and collaborators to conduct clinical trials, manufacture its product candidate, and develop and commercialize its product candidate; the Company’s ability to compete successfully against other drug candidates; and volatility in the price of the Company’s common stock. Accordingly, investors should not rely upon forward-looking statements as predictions of future events. Except as required by applicable law, the Company undertakes no obligation to update publicly or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Additionally, investors should read the risk factors in the section titled “Risk Factors” set forth in Part II, Item 1A of the Company’s Quarterly Report on Form 10-Q filed on August 13, 2026, in the preliminary prospectus supplement relating to the Offering, and in the Company’s other filings, each of which is on file with the Securities and Exchange Commission.

Pyxis Oncology Contact:
IR@pyxisoncology.com

HOUSTON, Sept. 29, 2026 (GLOBE NEWSWIRE) — Plains All American Pipeline, L.P. (Nasdaq: PAA) and Plains GP Holdings (Nasdaq: PAGP) (collectively, “Plains”) announced that Dean Liollio has been appointed to serve as Executive Vice President and Chief Operating Officer of Plains effective as of October 2, 2026. Mr. Liollio replaces Chris Chandler, the current EVP and COO, who is resigning from Plains to pursue other interests and not due to any disagreement relating to the company’s operations, policies or practices.

Mr. Liollio, age 67, served as Senior Vice President, Special Projects, of Plains from June 2024 until his appointment as EVP and COO in October 2026. He previously served as President of Plains Midstream Canada from 2020 until 2024, as President of PAA Natural Gas Storage from 2008 until 2020 and as President of Plains Gas Solutions from 2016 until 2020. Prior to joining Plains in 2008, Mr. Liollio held a number of executive roles including serving as President, Chief Executive Officer and Director of EnergySouth, Inc. and as President and Chief Operating Officer of Centerpoint’s natural gas distribution operations across a five-state area including Houston. Mr. Liollio holds a Bachelor of Science degree in Industrial Engineering from Texas A&M University.

“We congratulate Dean on his promotion to the EVP and COO role. Dean is immensely qualified to take on this key leadership role as he has been a member of our executive committee and has been instrumental in executing on our recent initiatives,” said Willie Chiang, Chairman, CEO and President. “I would also like to thank Chris for his many contributions to Plains and wish him the best in his future endeavors.”

About Plains
PAA is a publicly traded master limited partnership that owns and operates midstream energy infrastructure and provides logistics services for crude oil. PAA owns an extensive network of pipeline gathering and transportation systems, in addition to terminaling, storage, and other infrastructure assets serving key producing basins, transportation corridors and major market hubs and export outlets in the United States and Canada.

PAGP is a publicly traded entity that owns an indirect, non-economic controlling general partner interest in PAA and an indirect limited partner interest in PAA, one of the largest energy infrastructure and logistics companies in North America. 

PAA and PAGP are headquartered in Houston, Texas. More information is available at www.plains.com.

Investor Relations Contacts:
Blake Fernandez
Ross Hovde
PlainsIR@plains.com
(866) 809-1291

RENO, Nev., Sept. 29, 2026 (GLOBE NEWSWIRE) — Employers Holdings, Inc. (the “Company”) (NYSE:EIG) will release its third quarter 2026 financial results after market close on Wednesday, October 28, 2026, after which these materials will be available on the Company’s website at www.employers.com through the “Investors” link.

Conference Call Details
The Company will review these financial results via a conference call and webcast on Thursday, October 29, 2026, at 11:00 a.m. ET / 8:00 a.m. PT.

To participate in the live conference call, you must register here. Once registered you will receive a dial-in number and a unique PIN number. The webcast will be accessible on the Company’s website at www.employers.com through the “Investors” link.

An archived version of the webcast will be accessible on the Company’s website following the live call.

About EMPLOYERS
Employers Holdings, Inc. (NYSE: EIG), is a holding company with subsidiaries that are specialty providers of workers’ compensation insurance, excess workers’ compensation, and related services (collectively “EMPLOYERS®”) focused on small and mid-sized businesses engaged in lower hazard industries with its guaranteed cost product and self-insured enterprises with its excess workers’ compensation product. EMPLOYERS leverages over a century of experience to deliver comprehensive coverage solutions that meet the unique needs of its customers. Drawing from its long history and extensive knowledge, EMPLOYERS empowers businesses by protecting their most valuable asset – their employees – through exceptional claims management, loss control, and risk management services, to help businesses create safer work environments.

EMPLOYERS is also proud to offer Cerity®, which is focused on providing digital-first, direct-to-consumer workers’ compensation insurance solutions with fast and affordable coverage options through a user-friendly online platform.

EMPLOYERS operates throughout the United States, apart from four states that are served exclusively by their state funds. Workers’ Compensation insurance is offered through Employers Insurance Company of Nevada, Employers Compensation Insurance Company, Employers Preferred Insurance Company, Employers Assurance Company, and Cerity Insurance Company, and Excess Workers’ Compensation is offered through Employers Assurance Company. Each of EMPLOYERS insurance subsidiaries is rated A (Excellent) by AM Best. Not all companies do business in all jurisdictions. EIG Services, Inc., and Cerity Services, Inc., are subsidiaries of Employers Holdings, Inc. EMPLOYERS® is a registered trademark of EIG Services, Inc., and Cerity® is a registered trademark of Cerity Services, Inc. For more information, please visit www.employers.com, www.employers.com/excess-workers-compensation/, and www.cerity.com.

Contact Information
Michael Pedraja (775) 327-2706 or mpedraja@employers.com

MIAMI, Sept. 29, 2026 (GLOBE NEWSWIRE) — Laureate Education, Inc. (NASDAQ: LAUR) plans to release results for the quarter ended September 30, 2026, on Thursday, October 29, 2026, before the stock market opens. Following the release, the Company will host a conference call with investors and analysts at 8:30 a.m. ET to discuss the third quarter results and the Company’s business outlook.

Interested parties are invited to listen to the earnings conference call by registering here to receive dial in information.

The webcast of the conference call, including replays, and a copy of the earnings release and the related slides will be made available through the Investor Relations section of the Company’s website at www.laureate.net.

About Laureate Education, Inc.

Laureate Education, Inc. operates five higher education institutions across Mexico and Peru, enrolling approximately 500,000 students in high-quality undergraduate, graduate, and specialized degree programs through campus-based and online learning. Our universities have a deep commitment to academic quality and innovation, strive for market-leading employability outcomes, and work to make higher education more accessible. At Laureate, we know that when our students succeed, countries prosper, and societies benefit.

Investor Relations Contact:
ir@laureate.net

Media Contacts:
Laureate Education, Inc.
Adam Smith
adam.smith@laureate.net
U.S.: +1 (443) 255 0724

MINNEAPOLIS, Sept. 29, 2026 (GLOBE NEWSWIRE) — Vireo Growth Inc. (CSE: VREO) (OTCQX: VREOF) (“Vireo” or the “Company”), a leading cannabis company and agricultural markets platform, today announced that it has entered into a Put/Call Agreement (the “Put/Call Agreement”) with Battle Green Holdings SR LLC (the “Note Holder”), pursuant to which the Note Holder may cause Vireo to acquire, or Vireo may elect to acquire, a loan issued pursuant to a promissory note (the “Note”) issued by BG Ohio SPV LLC to the Note Holder.

Pursuant to the terms of the Put/Call Agreement, the Note Holder will have the right, but not the obligation, to cause Vireo to acquire the Note (the “Put Right”) and Vireo will have the right, but not the obligation, to purchase the Note (the “Call Right”), in each case by issuing Vireo subordinate voting shares (“Vireo Shares”) at a price of US$19.50 per Vireo Share in the case of the Put Right or US$18.60 per Vireo Share in the case of the Call Right. In addition, at the maturity date of the Note, if neither the Put Right nor the Call Right has been exercised, Vireo will acquire the Note by issuing Vireo Shares at the trailing 30-day volume weighted average price of the Vireo Shares (the “Maturity Call Right”). Additional Vireo Shares may be issuable in respect of accrued interest on the Note, subject to Vireo’s right to pay such interest in cash. The Put/Call Agreement has a term of three years. If the Put Right or Call Right is exercised, Vireo would issue a maximum of 972,905 Vireo Shares, based on a principal amount under the Note of US$18,096,028. If the Maturity Call Right is exercised, the number of Vireo Shares issuable will be determined based on the trailing 30-day volume weighted average price at the time of exercise, subject to applicable CSE pricing minimums. No Vireo Shares will be issued unless and until the Put Right, Call Right, or Maturity Call Right is exercised and all applicable conditions have been satisfied.

About Vireo Growth Inc.

Vireo Growth Inc. (CSE: VREO; OTCQX: VREOF) is a leading vertically integrated cannabis company building a broad platform across cannabis and adjacent agricultural markets. The Company operates cultivation, manufacturing, retail dispensaries, home delivery, distribution, and agricultural supply businesses across the United States, creating exposure to both cannabis and complementary adjacent markets. With operations in 10 states and more than 170 dispensaries nationwide, Vireo combines disciplined capital allocation, strategic acquisitions, and local market execution to scale its platform and drive long-term shareholder value. The Company is focused on expanding market share and strengthening its portfolio of consumer brands and services, while supporting the customers, employees, shareholders, and communities it serves. For more information about Vireo, visit www.vireogrowth.com.

Forward-Looking Information

This press release contains “forward-looking information” or “forward-looking statements” within the meaning of applicable United States and Canadian securities legislation (referred to herein as “forward-looking information”). Forward-looking information contained in this press release may be identified by the use of words such as “should,” “believe,” “estimate,” “would,” “looking forward,” “may,” “continue,” “expect,” “expected,” “will,” “likely,” “subject to,” and variations of such words and phrases, or any statements or clauses containing verbs in any future tense. Forward-looking information in this press release includes, without limitation, whether the Put Right, Call Right or Maturity Call Right will be exercised; the potential acquisition of the Note and the issuance of Vireo Shares pursuant to the Put/Call Agreement; the potential issuance amount and timing of any Vireo Shares pursuant to the Put/Call Agreement; and the potential impact of the Put/Call Agreement on the trading price of the Vireo Shares. These statements should not be read as guarantees of future performance or results.

Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, the reader should not place undue reliance on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to: the potential dilutive impact and overhang resulting from the possible issuance of Vireo Shares in connection with the Put/Call Agreement; the Company’s ability to maintain relationships with suppliers, customers, employees and other third parties; the nature, cost, impact and outcome of pending and future litigation, other legal or regulatory proceedings, or governmental investigations and actions; risks related to the timing and content of adult-use legislation in markets where the Company currently operates; current and future market conditions, including the market price of the subordinate voting shares of the Company; risks related to epidemics and pandemics; federal, state, local, and foreign government laws, rules, and regulations, including federal and state laws and regulations in the United States relating to cannabis operations in the United States and any changes to such laws or regulations; operational, regulatory and other risks; execution of business strategy; management of growth; difficulties inherent in forecasting future events; conflicts of interest; risks inherent in an agricultural business; risks inherent in a manufacturing business; liquidity and the ability of the Company to raise additional financing to continue as a going concern; the Company’s ability to meet the demand for flower in its various markets; our ability to dispose of our assets held for sale at an acceptable price or at all; and risk factors set out in the Company’s Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q, which are available on EDGAR with the U.S. Securities and Exchange Commission at www.sec.gov and filed with the Canadian securities regulators and available under the Company’s profile on SEDAR+ at www.sedarplus.com.

The statements in this press release are made as of the date of this release. Except as required by law, we undertake no obligation to update any forward-looking statements or forward-looking information to reflect events or circumstances after the date of such statements.

For Vireo, contact:
Lynn Ricci
Director Investor Relations & Corporate Communications
investor@vireogrowth.com
781-956-7052

Tel-Aviv, Israel, Sept. 29, 2026 (GLOBE NEWSWIRE) — Ellomay Capital Ltd. (NYSE American; TASE: ELLO) (“Ellomay” or the “Company”), a renewable energy and power generator and developer of renewable energy and power projects in Europe, USA and Israel, announced today that its Spanish indirectly held wholly-owned subsidiary, Ellomay Solar S.L., which owns a 28 MWp solar facility in Talaván, Cáceres, Spain, received a battery storage grid access and connection permit for a project with a capacity for up to 22.2 MW /100.3 MWh (4.5-hour) (the “BESS Facility”). The BESS Facility also received a permit to charge 22.2 MW electricity from the grid. The charging permit is expected to increase the flexibility and profitability of the project.

The BESS Facility will be constructed on land already leased to Ellomay Solar. Ellomay currently expects that construction of the BESS Facility will commence in the beginning of 2027 and will be completed in the fourth quarter of 2027.

Ran Fridrich, CEO and Board member of Ellomay, said: “As previously disclosed by Ellomay, battery storage is a core growth engine for Ellomay, and we are focusing our efforts in markets where the need for flexibility is growing fastest, primarily Spain and Italy. The permit received by Ellomay Solar represents an important milestone in our strategy. The combination of solar generation and long-duration storage from Ellomay Solar’s facility and from the grid will provide a great degree of flexibility to Ellomay Solar, helping us make more effective use of renewable energy while supporting the evolving needs of the power system. We are pleased to advance the BESS Project and continue developing solutions that contribute to a more flexible and resilient energy future.”

About Ellomay Capital Ltd.

Ellomay is an Israeli based company whose shares are registered with the NYSE American and with the Tel Aviv Stock Exchange under the trading symbol “ELLO”. Since 2009, Ellomay focuses its business in the renewable energy and power sectors in Europe, USA and Israel.

To date, Ellomay has evaluated numerous opportunities and invested significant funds in the renewable, clean energy and natural resources industries in Israel, Italy, Spain, the Netherlands and USA, including:

  • Approximately 335.9 MW of operating solar power plants in Spain (including a 300 MW solar plant in owned by Talasol, which is 51% owned by the Company) and 51% of approximately 48 MW of operating solar power plants in Italy;
     
  • Groen Gas Goor B.V., Groen Gas Oude-Tonge B.V. and Groen Gas Gelderland B.V., project companies operating anaerobic digestion plants in the Netherlands, with a green gas production capacity of approximately 3 million, 3.8 million and 9.5 million Nm3 per year, respectively;
     
  • 83.333% of Ellomay Pumped Storage (2014) Ltd., which is involved in a project to construct a 156 MW pumped storage hydro power plant in the Manara Cliff, Israel;
     
  • 51% of solar projects in Italy with an aggregate capacity of 150 MW that are under construction;
     
  • Solar projects in Italy with an aggregate capacity of 227 MW that have reached “ready to build” status; and
     
  • Solar projects in the Dallas Metropolitan area, Texas, USA with an aggregate capacity of approximately 49 MW that are connected to the grid and 14 MW that is awaiting connection to the grid.

For more information about Ellomay, visit http://www.ellomay.com.


Information Relating to Forward-Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties, including statements that are based on the current expectations and assumptions of the Company’s management. All statements, other than statements of historical facts, included in this press release regarding the Company’s plans and objectives, expectations and assumptions of management are forward-looking statements. The use of certain words, including the words “estimate,” “project,” “intend,” “expect,” “believe” and similar expressions are intended to identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The Company may not actually achieve the plans, intentions or expectations disclosed in the forward-looking statements and you should not place undue reliance on the Company’s forward-looking statements. Various important factors could cause actual results or events to differ materially from those that may be expressed or implied by the Company’s forward-looking statements, including delays and difficulties in commencing and finalizing the construction of the BESS Facility, changes in electricity prices and demand, regulatory changes increases in interest rates and inflation, changes in the supply and prices of resources required for the operation of the Company’s facilities (such as waste and natural gas) and in the price of oil, the impact of the war and hostilities in Israel and Gaza and between Israel and Iran, the impact of the continued military conflict between Russia and Ukraine, technical and other disruptions in the operations or construction of the power plants owned by the Company, inability to obtain the financing required for the development and construction of projects, increases in interest rates and inflation, changes in exchange rates, delays in development, construction, or commencement of operation of the projects under development, failure to obtain permits – whether within the set time frame or at all, climate change, and general market, political and economic conditions in the countries in which the Company operates, including Israel, Spain, Italy and the United States. These and other risks and uncertainties associated with the Company’s business are described in greater detail in the filings the Company makes from time to time with the Securities and Exchange Commission, including its Annual Report on Form 20-F. The forward-looking statements are made as of this date and the Company does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:

Kalia Rubenbach (Weintraub)
CFO
Tel: +972 (3) 797-1111
Email: hilai@ellomay.com

New awards expand contracted business visibility across YYForce’s Singapore integrated facility management operations, with all contracts commencing in October 2026 and principal service periods extending approximately three years

SINGAPORE, Sept. 29, 2026 (GLOBE NEWSWIRE) — YYForce Inc. (Nasdaq: YFOR) (“YYForce” or the “Company”), an AI-enabled workforce management and integrated facility management (“IFM”) provider, today announced that its Singapore subsidiary, Hong Ye Group Pte. Ltd. (“Hong Ye Group”), has been awarded multiple new commercial cleaning and related facility services contracts in Singapore with an aggregate contract value of approximately S$15.96 million (approximately US$12.5 million).

The newly awarded contracts cover multiple properties in Singapore, are scheduled to commence across October 2026, and have varying service periods, with the principal contracts extending for approximately three years. Based on current contractual schedules, aggregate contract values are expected to be approximately S$5.57 million in Year 1, S$5.55 million in Year 2 and S$4.84 million in Year 3.

Key Contract Facts

Metric Details
Aggregate Contract Value Approximately S$15.96 million
Business Unit Hong Ye Group Pte. Ltd., YYForce’s Singapore subsidiary
Services Commercial cleaning and related facility services
Market Singapore
Contract Commencement October 2026
Principal Contract Duration Approximately three years
Year 1 Contract Value Approximately S$5.57 million
Year 2 Contract Value Approximately S$5.55 million
Year 3 Contract Value Approximately S$4.84 million


Expanding Multi-Year Contracted Business Visibility

The new awards expand Hong Ye Group’s portfolio of contracted commercial cleaning and facility services work in Singapore and provide YYForce with additional multi-year contracted business visibility, supported by a unified contract commencement in October 2026.

The awards follow YYForce’s recently reported first-half 2026 results, in which IFM revenue increased 11.1% year over year to approximately US$16.06 million. The Company reported that IFM growth in the period was supported by new contract wins, renewals of existing projects and full-period contributions from subsidiaries acquired in 2025.

Contract Value and Revenue Recognition. Aggregate contract value is distinct from revenue recognized for accounting purposes. With all contracts commencing in October 2026, actual revenue recognition will depend on ongoing service delivery, contractual terms, customer requirements and applicable accounting standards. There can be no assurance that the full aggregate contract value will be recognized as revenue according to the current anticipated schedule.

Executive Commentary

“These new multi-year contract awards expand our commercial services business in Singapore and strengthen the contracted business visibility of Hong Ye Group as we head into our October commencement,” said Mike Fu, Chief Executive Officer of YYForce.

“As we execute our integrated facility management strategy, our focus is on combining disciplined frontline service delivery with workforce technology, intelligent scheduling, AI and automation. These contracts expand the operating base through which we can continue improving productivity, service consistency and scalability over time.”

Supporting YYForce’s Integrated Facility Management Strategy

Hong Ye Group is an important component of YYForce’s IFM operations in Singapore. YYForce’s strategy is to combine established frontline facility services with technology-enabled workforce management and, over time, increasing levels of AI, automation and robotics.

Human Workforce + Workforce Technology + IFM + AI + Automation + Robotics

The Company believes this model can support improved workforce deployment, service consistency, operating efficiency and scalability. The newly awarded contracts provide an expanded operating base through which YYForce can continue developing and deploying technology-enabled solutions within its facility services operations.

About YYForce Inc.

YYForce Inc. (Nasdaq: YFOR) is an AI-enabled workforce management and integrated facility management provider headquartered in Singapore and operating across Asia and beyond. Through its workforce technology and IFM businesses, YYForce provides workforce deployment, management and facility services solutions across multiple service industries.

The Company’s workforce platform, YY Circle, supports workforce deployment and management across sectors including hospitality, food and beverage, retail and other service industries. Within its IFM operations, YYForce combines frontline facility services with technology solutions designed to improve workforce productivity and operational efficiency.

YYForce’s long-term strategy is centered on building an integrated future workforce ecosystem in which human workers, intelligent software, automation and robotics increasingly work together to deliver services more efficiently.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by words such as “may,” “will,” “should,” “expects,” “anticipates,” “estimates,” “believes,” “plans,” “intends,” “projects,” “predicts,” “potential,” “continue,” “target,” or similar expressions.

These forward-looking statements include, among other things, statements regarding anticipated contract performance and revenue recognition, the Company’s integrated facility management strategy, the integration of workforce technology, artificial intelligence, automation and robotics into its operations, operational efficiency, scalability and future growth strategy.

Forward-looking statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied. These risks and uncertainties include, among others, customer requirements, contract commencement and performance, labor availability and costs, competitive conditions, economic and market conditions, technology implementation, regulatory developments and other risks described in YYForce’s filings with the U.S. Securities and Exchange Commission.

Readers are encouraged to review the Company’s filings with the SEC, including the “Risk Factors” section of its most recent annual report on Form 20-F and subsequent filings. YYForce undertakes no obligation to publicly update or revise any forward-looking statements except as required by applicable law.

Investor Relations Contacts

Jason Zhi Yong Phua
Chief Financial Officer
YYForce Inc.
enquiries@yyforce.ai

Piacente Financial Communications
yfor@thepiacentegroup.com

RADNOR, Pa., Sept. 29, 2026 (GLOBE NEWSWIRE) — Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone, announced today that, on September 28, 2026, the Compensation Committee of Mineralys’ Board of Directors granted inducement stock option awards covering an aggregate of 46,430 shares and inducement restricted stock unit awards covering an aggregate of 34,823 shares of Mineralys common stock to two new non-executive employees.

The awards were granted under Mineralys’ 2025 Employment Inducement Incentive Award Plan, which provides for the granting of equity awards to new employees of Mineralys. The option awards will vest over a four-year period, with 25% of the total shares underlying the awards vesting on the first anniversary of the awards’ vesting commencement date, September 28, 2026, and 1/48th of the total shares underlying the awards vesting following each one-month period thereafter, subject to continued service. The restricted stock unit awards will vest over a four-year period, with 25% of the shares vesting on each of the first four anniversaries of the awards’ vesting commencement date, September 28, 2026, subject to continued service. The awards were granted as an inducement material to the new non-executive employees entering into employment with Mineralys, in accordance with Nasdaq Listing Rule 5635(c)(4).

About Mineralys

Mineralys Therapeutics is a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is an investigational, proprietary, orally administered, highly selective aldosterone synthase inhibitor. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn, X and Bluesky.

Contact:

Investor Relations

investorrelations@mineralystx.com

BALA CYNWYD, Pa., Sept. 29, 2026 (GLOBE NEWSWIRE) — Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the appointment of John Harlow as President and Chief Operating Officer, effective September 29, 2026, reporting to Carole Ben-Maimon, M.D., Larimar’s Chief Executive Officer. Mr. Harlow joins Larimar with more than 25 years of commercial, operational and business development experience across the biopharmaceutical industry.

“As nomlabofusp advances toward potential approval, we are excited to welcome John to our executive team,” said Carole Ben-Maimon, M.D., Chief Executive Officer of Larimar. “His commercial and operational leadership, coupled with his proven ability to translate strategy into execution, will be instrumental as we scale the organization and prepare to bring nomlabofusp to patients worldwide.”

Mr. Harlow added, “Larimar has a unique opportunity to deliver the first potential disease-modifying therapy for adults and pediatric patients living with Friedreich’s ataxia. I look forward to working with Carole and this talented team to deliver a successful launch and position the company for long-term growth.”

Most recently, he served as Chief Commercial Officer of Esperion Therapeutics, where he led commercial operations, business development and global alliance management. Previously, he served as Chief Commercial Officer of Melinta Therapeutics, where he built a robust commercial infrastructure with a high-performing team while achieving significant revenue growth and sustained profitability ahead of its 2025 acquisition by CorMedix. Earlier in his career, Mr. Harlow held executive leadership roles at Baudax Bio, Recro Pharma and Endo Pharmaceuticals, as well as commercial and marketing leadership roles at Shionogi, Alpharma/King Pharmaceuticals, Novartis and Janssen. His earlier experience also includes serving as an equity research analyst at Merrill Lynch. Mr. Harlow holds an MBA in Pharmaceutical Management from Seton Hall University and a BS in Biology from Lehigh University.

Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

In connection with Mr. Harlow’s appointment, the Compensation Committee of the Board of Directors of the Company approved an inducement award, in accordance with Nasdaq Listing Rule 5635(c)(4), to Mr. Harlow, to be granted on September 29, 2026 consisting of a (i) non-qualified stock option (“Option Award”) to purchase 800,000 shares of the Company’s common stock at an exercise price equal to the closing price per share of the Company’s common stock as reported on the Nasdaq Global Market on the date of grant and (ii) restricted stock unit award in respect of 50,000 shares of the Company’s common stock (“RSU Award” and together with the Option Award, the “Equity Awards”). The Equity Awards were granted as an inducement material to his acceptance of employment as President and Chief Operating Officer of the Company. The Option Award will vest over a four-year period, with 25% of the Option Award vesting on the first anniversary of the date of grant, and the remaining 75% of the Option Award vesting in substantially equal monthly installments over thirty-six (36) months. The RSU Award will vest in four (4) substantially equal annual installments, beginning on the first anniversary of the date of grant. The Equity Awards are subject to Mr. Harlow’s continued service with the Company through the applicable vesting dates and were granted outside the terms of the Company’s 2020 Equity Incentive Plan.

About Larimar Therapeutics
Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar’s lead compound, nomlabofusp, is being developed as a potential treatment for Friedreich’s ataxia. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: https://larimartx.com.

Forward-Looking Statements
This press release contains forward-looking statements that are based on Larimar’s management’s beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including but not limited to statements regarding Larimar’s ability to develop and commercialize nomlabofusp and any other planned product candidates, Larimar’s planned research and development efforts, including the timing of its nomlabofusp clinical trials, dosing of the first patient in a global confirmatory Phase 3 study, interactions and filings with the FDA, the safety and therapeutic potential of nomlabofusp, expectations regarding the timing of completion of the BLA submission, the expectations of the timing of, and potential for, accelerated approval or accelerated access, time to launch and market and overall development plans and other matters regarding Larimar’s business strategies, ability to raise capital, use of capital, results of operations and financial position, and plans and objectives for future operations.

In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors include, among others, the success, cost and timing of Larimar’s product development activities, nonclinical studies and clinical trials, including nomlabofusp clinical milestones and continued interactions with the FDA; that preliminary clinical trial results may differ from final clinical trial results, that earlier non-clinical and clinical data and testing of nomlabofusp may not be predictive of the results or success of later non-clinical or clinical trials, and assessments; delays in patient recruitment, including as a result of changes in clinical protocols and adverse events; that the FDA may not ultimately agree with Larimar’s nomlabofusp development strategy; Larimar’s ability to submit BLA modules on the intended timeline; Larimar’s ability to realize the benefits of Breakthrough Therapy Designation; the potential impact of public health crises on Larimar’s future clinical trials, manufacturing, regulatory, nonclinical study timelines and operations, and general economic conditions; Larimar’s ability and the ability of third-party manufacturers Larimar engages, to optimize and scale nomlabofusp’s manufacturing process; Larimar’s ability to obtain regulatory approvals for nomlabofusp and future product candidates; Larimar’s ability to develop sales and marketing capabilities, whether alone or with potential future collaborators, and to successfully commercialize any approved product candidates; Larimar’s ability to raise the necessary capital to conduct its product development activities; and other risks described in the filings made by Larimar with the Securities and Exchange Commission (SEC), including but not limited to Larimar’s periodic reports, including the annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, filed with or furnished to the SEC and available at www.sec.gov. These forward-looking statements are based on a combination of facts and factors currently known by Larimar and its projections of the future, about which it cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent Larimar’s management’s views only as of the date hereof. Larimar undertakes no obligation to update any forward-looking statements for any reason, except as required by law.

Investor Contact:
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com
(212) 915-2569
Company Contact:
Michael Celano
Chief Financial Officer
mcelano@larimartx.com
(484) 414-2715

  • Companies will collaborate to develop advanced memory structures, chip stacking technologies and materials engineering innovations to increase AI memory performance
  • KIOXIA joins Applied Materials’ growing EPIC Center ecosystem, which includes chipmakers, chip designers, equipment partners and universities

SANTA CLARA, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) — Applied Materials, Inc., the leader in materials engineering solutions for the semiconductor industry, today announced that KIOXIA Corporation, a leading global supplier of flash memory and solid state drives (SSDs), will join Applied’s EPIC Center in Silicon Valley as an innovation partner to advance next-generation memory technologies. The companies will work together at the EPIC Center on advanced memory-cell and structure creation, multi-chip stacking architectures, and new materials engineering approaches designed to increase memory density and performance for the AI era.

“AI infrastructure requires memory solutions that can deliver dramatically higher density, greater bandwidth and improved energy efficiency,” said Gary Dickerson, President and CEO of Applied Materials. “By bringing KIOXIA’s deep expertise in memory technology together with Applied’s materials engineering innovations at the EPIC Center, we’re creating a powerful partnership to define what’s possible in next-generation memory.”

“At KIOXIA, we have always believed that the possibility of memory is defined by the ability to stretch the boundaries of materials and process innovation,” said Hiroo Ota, President and CEO of KIOXIA Corporation. “Our collaboration with Applied Materials reflects our shared commitment to driving memory innovation, and we are excited to partner at the EPIC Center to achieve advanced breakthroughs.”

Through the EPIC Center partnership, Applied Materials and KIOXIA will collaborate on R&D initiatives focused on the most critical challenges in next-generation memory innovation. Areas of focus include:

  • Advanced memory cell and structure creation to develop more capable, higher-density memory architectures for AI applications
  • Multi-chip stacking for next-generation memory to enable chip integration that increases memory density and performance within constrained form factors
  • Advanced packaging for stacked memory to improve integration and interconnect performance in complex multi-die memory solutions
  • Materials engineering innovations that enable next-generation memory structures while supporting manufacturability at scale

“Memory is at the center of the AI innovation roadmap, and the challenges of increasing memory density while managing cost and complexity require breakthroughs across materials, equipment and process technology,” said Dr. Prabu Raja, President of the Semiconductor Products Group at Applied Materials. “We look forward to partnering with KIOXIA at the EPIC Center, where our teams will drive advances in AI memory through deep co-innovation.”

“Partnering with Applied Materials at the EPIC Center gives us a unique environment to tackle the hardest challenges in next-generation memory,” said Minori Kajimoto, General Manager of Advanced Memory Development at KIOXIA. “By having top innovators from KIOXIA and Applied Materials working side by side, we aim to accelerate the commercialization of breakthroughs in memory and packaging technologies that achieve new levels of integration and performance for AI computing.”

Applied’s new, $5 billion* EPIC (Equipment and Process Innovation and Commercialization) Center in Silicon Valley represents the largest-ever U.S. investment in advanced semiconductor equipment R&D. The center, which will be operationally ready this year, is designed from the ground up to dramatically reduce the time it takes to commercialize breakthrough technologies from early-stage research to full-scale manufacturing. For chipmakers, the EPIC Center will provide earlier access to Applied’s R&D portfolio, faster cycles of learning and accelerated transfer of next-generation technologies into high-volume manufacturing, within a secure collaborative environment. In addition, the co-innovation programs at the EPIC Center will provide Applied with greater multi-node visibility to guide R&D investments while increasing R&D productivity and value sharing.

*Capital spending is expected to scale over time to approximately $5 billion as customer projects commence.

Forward-Looking Statements
This press release contains forward-looking statements, including those regarding Applied’s investment and growth strategies, the development of new materials and technologies, industry outlook and technology requirements, the plans and expectations for the EPIC Center, and other statements that are not historical facts. These statements and their underlying assumptions are subject to risks and uncertainties and are not guarantees of future performance. Factors that could cause actual results to differ materially from those expressed or implied by such statements include, without limitation: the demand for semiconductors and customers’ technology requirements; the ability to develop new and innovative technologies; the ability to obtain and protect intellectual property rights in key technologies; the ability to achieve the objectives of the EPIC Center; and other risks and uncertainties described in Applied’s filings with the Securities and Exchange Commission, including Applied’s most recent Forms 10-K, 10-Q and 8-K. All forward-looking statements are based on management’s current estimates, projections and assumptions, and Applied assumes no obligation to update them.

About Applied Materials
Applied Materials, Inc. (Nasdaq: AMAT) is the leader in materials engineering solutions that are at the foundation of virtually every new semiconductor and advanced display in the world. The technology we create is essential to advancing AI and accelerating the commercialization of next-generation chips. At Applied, we push the boundaries of science and engineering to deliver material innovation that changes the world. Learn more at www.appliedmaterials.com.

Contacts:

Applied Materials
Ricky Gradwohl (editorial/media) 408.235.4676
Mike Sullivan (financial community) 408.986.7977

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.